PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib

Sorafenib is currently the only systemic agent approved for treatment of advanced hepatocellular carcinoma (HCC). However, intrinsic and acquired resistance to sorafenib remains a great challenge with respect to improving the prognoses of patients with HCC. The cyto-protective functions of autophagy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Zhang, Kai, Chen, Jing, Zhou, Hao, Chen, Ying, Zhi, Yingru, Zhang, Bei, Chen, Longbang, Chu, Xiaoyuan, Wang, Rui, Zhang, Chunni
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833744/
https://ncbi.nlm.nih.gov/pubmed/29472524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0344-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados